Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma

NCT00729118 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT00729118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00729118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
September 26, 2008
Completion date
May 4, 2020
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, plasma cell neoplasm